Investors
News & Events
Press Releases
The latest Inventiva investor and corporate press releases.
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Inventiva Reports 2026 First Quarter Financial Information¹
Inventiva Announces Filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
Inventiva Reports 2025 Full Year Results and Provides a Business Update
Inventiva Reports Preliminary 2025¹ Fiscal Year Financial Results
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Inventiva to Present Abstracts at the EASL Congress 2026
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
Inventiva to Participate in Four Upcoming March Investor Conferences
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Inventiva reports 2025 Third Quarter Financial Information
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Inventiva announces pricing of upsized public offering of approximately $150M American Depositary Shares
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
Inventiva announces launch of public offering
Combined General Meeting of November 27, 2025 – Availability of the preparatory documents
Inventiva Announces the Implementation of a New ATM Program
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
Inventiva to Host Analyst and Investor Event on October 8, 2025
Inventiva to Participate in Upcoming September Investor Conferences
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inventiva Reports Preliminary 2025 First-Half Financial Information
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Inventiva receives $10 million milestone payment from CTTQ
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
Inventiva reports 2025 First Quarter Financial Information¹
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
Combined General Meeting of May 22, 2025 – Availability of the preparatory documents
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of the results of its analysis of new and specific non-invasive biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Inventiva reports its 2024 full year results and provides a business update
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Inventiva reports preliminary 2024¹ fiscal year financial results and provides a business update
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
Inventiva reports 2024 Third Quarter Financial Information
Statement of total voting rights and shares forming the company’s share capital as of November 4th, 2024
Combined General Meeting of December 11, 2024 – Availability of the preparatory documents
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
Inventiva Reports Preliminary 2024 First-Half Financial Information
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
Inventiva announces a €20.1 million issuance of royalty certificates
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
Description of The Share Repurchase Program Authorised by The Ordinary General Meeting of 20 June 2024
Combined General Meeting of June 20, 2024 – Availability of the preparatory documents
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
Inventiva reports 2024 First Quarter Financial Information and provides a corporate update
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
Inventiva announces the nomination of Andre Turenne as Director
Inventiva reports its 2023 full-year results
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
Inventiva reports preliminary 2023 fiscal year financial information and provides an update on its clinical trial NATiV3
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
Inventiva reports 2023 Third Quarter Financial Information
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
Inventiva reports its 2023 first-half financial results and provides a corporate update
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023
Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023
Description of the share repurchase program authorised by the ordinary general meeting of 25 May 2023
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate the clinical development of lanifibranor in China
Inventiva reports 2023 First Quarter Financial Information and provides a corporate update
Combined General Meeting of May 25, 2023. Availability of the preparatory documents
Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
Inventiva reports its 2022 Full-Year Results
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
Inventiva reports preliminary financial results for Full-Year 2022
Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
Combined General Meeting of January 25, 2023. Availability of the preparatory documents
Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
Inventiva announces a new Director of the Board of Directors
Inventiva reports 2022 Third Quarter Financial Information
Inventiva provides an update on the development of cedirogant by AbbVie
Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022
Inventiva reports its 2022 first-half financial results and provides a corporate update
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
Inventiva Reports 2022 First-Half Financial Information
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
Update on Inventiva’s cash position and on the finance documentation with the European Investment Bank
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
Inventiva joins the Euronext Tech Leaders segment
Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association
Inventiva announces participation at several investors conferences in May and June 2022
Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022
Description of the share repurchase program authorised by the Ordinary General Meeting of 19 May 2022
Inventiva secures a €50 million credit facility from the European Investment Bank
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022
Combined General Meeting of May 19, 2022 Availability of the preparatory documents
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
Inventiva announces participation at several conferences in March 2022
Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
Inventiva reports cash position and revenues for Full-Year 2021
Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation
Inventiva announces participation at several conferences in January and February 2022
Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
Inventiva reports 2021 Third Quarter Financial Information
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021
Inventiva announces participation at several investor conferences in November 2021
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
Inventiva announces participation at several investor conferences in October 2021
Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors
Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
Inventiva reports 2021 first half financial results and provides a corporate update
Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
Inventiva’s 2021 First-Half Financial Results Presentation
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
Inventiva announces participation at several investor conferences in September 2021
Inventiva announces the implementation of an At-The-Market program in the United States
Inventiva Reports First-Half of 2021 Financial Information
Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event
Inventiva to participate at the Jefferies Virtual Healthcare Conference
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit
Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors
Shareholders Meeting of April 16, 2021 – Availability of the preparatory documents and methods for participating and voting
Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States
Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement
Inventiva to participate at several investor conferences in March 2021
Full-Year 2020: Cash position and revenues
Inventiva’s 2020 Full-Year Financial Results Presentation
Inventiva to present at the 39th Annual J.P. Morgan Healthcare Conference
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis
Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Q3 2020 Financial Information
Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH
Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference
Inventiva announces the appointment of Dr. Michael Cooreman as Chief Medical Officer
Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020
Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology
Inventiva to host a Key Opinion Leader webcast from the AASLD The Liver Meeting Digital Experience™ 2020
Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparcil
Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary session at The Liver Meeting Digital Experience™ 2020
Inventiva to participate at several investor conferences in October 2020
H1 2020 financial results and corporate business update
Inventiva to participate at several investor conferences in September 2020
Inventiva announces the closing of $107.7 million initial public offering on the Nasdaq Global Market
Inventiva announces the pricing of its initial public offering on the Nasdaq Global Market
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
Inventiva annonce la mise à disposition d’un prospectus dans le cadre de son offre au public d’actions ordinaires sous la formes d’ADS à l’occasion de son introduction en bourse sur le Nasdaq Global Market (only in French)
Inventiva announces the filing of an amended registration statement, including an estimated initial public offering price range
Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)
H1 2020 Financial Information
Inventiva Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing
Inventiva files registration statement for proposed initial public offering in the United States
Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH)
Inventiva to participate at the Jefferies Virtual Healthcare Conference
Inventiva secures a new patent for lanifibranor in China expanding the protection of its lead product candidate
Inventiva secures €10.0 m non-dilutive loan facility guaranteed by the French State in the context of the COVID-19 pandemic
Inventiva’s latest research on odiparcil’s mechanism of action published in leading peer-reviewed scientific journal PLOS ONE
Q1 2020 Financial Information
Shareholders Meeting of May 28, 2020 – Availability of the preparatory documents and methods for participating and voting at the meeting
Inventiva to provide an update on the NATIVE Phase IIb clinical trial in NASH during a Key Opinion Leader webcast
Inventiva provides a corporate business update in the context of the COVID-19 pandemic
Inventiva announces completion of patient visits for its Phase IIb clinical study with lanifibranor in NASH
2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway
Inventiva files a prospectus in the context of the admission to trading of new shares on Euronext Paris
Inventiva completes a capital increase of €15 m subscribed by existing shareholders
Full-Year 2019 : Cash position and revenues
Inventiva selected to present the positive results from its Phase IIa clinical study with odiparcil in MPS VI at the 16th « Annual WORLDSymposiumTM »
Inventiva admitted to the SRD “Long only” on the regulated market of Euronext Paris
Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI
Inventiva receives a €3.5 m milestone payment from AbbVie
Q3 2019 financial information and update on the partnership with Boehringer Ingelheim
Inventiva to present at the Jefferies 2019 London Healthcare Conference
Inventiva to participate at the H.C. Wainwright 3rd Annual NASH Investor Conference and the Gilbert Dupont NASH Day
Inventiva completes a capital increase of € 625,000 subscribed by Sofinnova Partners through Sofinnova Crossover I Fund
Inventiva receives FDA Fast Track designation for lead asset lanifibranor in NASH
H1 2019 financial results and corporate business update
Inventiva completes a capital increase of € 8.2 million subscribed by leading US and European biotech investors
Inventiva announces the positive recommendation of the 4 th and last DSMB of the Phase IIb clinical study with lanifibranor in NASH
Inventiva achieves a major milestone by completing patient recruitment for its Phase IIb clinical study with lanifibranor in NASH
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults
Inventiva secures a new European patent strengthening and extending the protection of its lead product candidate lanifibranor
New promising results on lanifibranor to be presented at The Liver Meeting® 2019
Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor
H1 20191 Financial Information and Corporate Business Update
Inventiva announces the creation of its Scientific Advisory Board
Inventiva Announces End of Patient Recruitment for its Phase IIa Trial in the Treatment of MPS VI
Nawal Ouzren and Heinz Maeusli appointed to Inventiva’s Board of Directors
Inventiva to Present at the Jefferies 2019 Healthcare Conference
Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH
Inventiva to present new results of its YAP-TEAD oncology program at the AACR Special Conference on The Hippo Pathway
Inventiva to Participate at the H.C. Wainwright Global Life Sciences Conference
Inventiva to Present Corporate Overview at the Cowen and Company 39th Annual Health Care Conference
Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH
Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis
New results on lanifibranor to be presented at the International Liver Congress™ 2019
Inventiva invited to present at the 37th Annual J.P. Morgan Healthcare Conference
Inventiva announces that it has been informed of the modification of the call option agreement concluded by BVF Partners L.P.
2018 Full-Year Results : Important Progress in R&D Portfolio and Solid Cash Position
Events
Upcoming and past investor events from the financial calendar.